Publications

Nuclear Imaging Study of the Pharmacodynamic Effects of Debio 1143, an Antagonist of Multiple Inhibitor of Apoptosis Proteins (IAPs), in…

SMAC Mimetic Debio 1143 and Ablative Radiation Therapy Synergize to Enhance Antitumor Immunity against Lung Cancer

The inhibitor of apoptosis protein (IAP) antagonist Debio 1143 enhances the immune response to anti-PD1/L1 inhibitors in vitro and in…

Chemosensitization to Carboplatin and Paclitaxel by IAP Inhibitor Debio 1143 in Ovarian Cancer Cell Lines: Signature Identification for Potential Patient…

Paclitaxel-Carboplatin With The Oral Iap Inhibitor Debio1143 In A Subset Of Patients With Recurrent Epithelial Ovarian Cancer (EOC): Phase I

Population pharmacokinetic analysis of the IAPs antagonist Debio 1143 and its major metabolite in oncologic patients

Phase 1 Study of Debio 1143 with Concurrent Chemo-Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Clinical Safety, Pharmacokinetics and Early Evidence of Activity of The Oral IAPs Inhibitor Debio 1143 in Combination with Carboplatin and…

SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells